Published in AIDS Patient Care STDS on May 23, 2013
Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS (2014) 0.99
Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care STDS (2017) 0.75
Caregivers' Support Network Characteristics Associated with Viral Suppression among HIV Care Recipients. AIDS Behav (2017) 0.75
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med (2000) 3.76
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. AIDS Patient Care STDS (2008) 1.47
Associations between HIV-related stigma, racial discrimination, gender discrimination, and depression among HIV-positive African, Caribbean, and Black women in Ontario, Canada. AIDS Patient Care STDS (2013) 1.42
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt) (2011) 1.15
Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS (2012) 1.09
Gender differences in the diagnosis and treatment of HIV. Gend Med (2007) 1.04
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Res Treat (2012) 1.00
Gender, sex, and HIV: how well are we addressing the imbalance? Curr Opin HIV AIDS (2008) 0.93
Impact of patient race on patient experiences of access and communication in HIV care. J Gen Intern Med (2008) 0.91
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother (2010) 0.90
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. AIDS Res Hum Retroviruses (2012) 0.87
HIV providers' perceptions of and attitudes toward female versus male patients. AIDS Patient Care STDS (2012) 0.87
Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat (2011) 0.83
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS (2011) 0.82
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2010) 2.25
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis (2011) 2.12
Spirituality and religion in patients with HIV/AIDS. J Gen Intern Med (2006) 1.99
HIV risk behaviors among African American men in Los Angeles County who self-identify as heterosexual. J Acquir Immune Defic Syndr (2002) 1.97
Comet 81P/Wild 2 under a microscope. Science (2006) 1.83
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis (2004) 1.52
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis (2004) 1.48
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses (2012) 1.35
Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDS (2011) 1.30
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS (2007) 1.25
Glutathione and nitrosoglutathione in macrophage defense against Mycobacterium tuberculosis. Infect Immun (2005) 1.17
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med (2012) 1.15
Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt) (2011) 1.15
Role of glutathione in macrophage control of mycobacteria. Infect Immun (2003) 1.14
A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis (2005) 1.12
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS (2011) 1.10
Incidence and prevalence of dementia in elderly adults with mental retardation without down syndrome. Am J Ment Retard (2004) 1.07
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis (2002) 1.07
Natural killer cells, glutathione, cytokines, and innate immunity against Mycobacterium tuberculosis. J Interferon Cytokine Res (2008) 1.06
Dementia in adults with mental retardation: assessment at a single point in time. Am J Ment Retard (2004) 1.05
Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS (2008) 1.03
HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis (2004) 1.03
Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir Ther (2011) 1.02
Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics (2012) 1.02
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. AIDS Res Treat (2012) 1.00
HIV health care services for Mexican migrants. J Acquir Immune Defic Syndr (2004) 1.00
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther (2010) 0.97
Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis (2007) 0.97
Change in quality of life after being diagnosed with HIV: a multicenter longitudinal study. AIDS Patient Care STDS (2009) 0.96
Health-related quality of life predicts survival, cytomegalovirus disease, and study retention in clinical trial participants with advanced HIV disease. J Clin Epidemiol (2003) 0.96
The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use. AIDS Care (2012) 0.96
Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther (2003) 0.96
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. J Acquir Immune Defic Syndr (2010) 0.96
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr (2007) 0.95
Changes in religiousness and spirituality attributed to HIV/AIDS: are there sex and race differences? J Gen Intern Med (2006) 0.94
Bacterial Signal Transduction by Cyclic Di-GMP and Other Nucleotide Second Messengers. J Bacteriol (2016) 0.93
Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation (2008) 0.91
Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther (2011) 0.90
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother (2010) 0.90
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials (2011) 0.89
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS (2002) 0.89
Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience. AIDS Res Hum Retroviruses (2012) 0.87
Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache (2002) 0.86
Stanford-Binet & WAIS IQ Differences and Their Implications for Adults with Intellectual Disability (aka Mental Retardation). Intelligence (2010) 0.85
Pregnancy rates and predictors in women with HIV/AIDS in Rio de Janeiro, Southeastern Brazil. Rev Saude Publica (2011) 0.84
Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat (2011) 0.83
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2004) 0.83
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. J Acquir Immune Defic Syndr (2016) 0.83
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS (2011) 0.82
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE). J Acquir Immune Defic Syndr (2014) 0.80
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals. J Clin Immunol (2011) 0.80
Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. AIDS Patient Care STDS (2003) 0.80
Intellectual Disability, Mild Cognitive Impairment, and Risk for Dementia. J Policy Pract Intellect Disabil (2013) 0.80
Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc (2012) 0.80
Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache (2003) 0.79
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine. AIDS (2014) 0.79
Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials (2010) 0.79
Nitric oxide regulation of L-arginine uptake in murine and human macrophages. Tuberculosis (Edinb) (2003) 0.79
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa. BMC Infect Dis (2014) 0.78
Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. J Antimicrob Chemother (2009) 0.78
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opin Pharmacother (2012) 0.78
The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol (2004) 0.77
How do patients with HIV/AIDS understand and respond to health value questions? J Gen Intern Med (2006) 0.77
Report from the 14th Retrovirus Conference. Metabolic complications: lipoatrophy, lipohypertrophy, and cardiovascular risk. AIDS Clin Care (2007) 0.77
Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE. Curr HIV Res (2013) 0.76
Cardiovascular risk factors and antiretroviral therapy. N Engl J Med (2003) 0.76
Report from the 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV. Treatment for patients with central fat accumulation. J Watch AIDS Clin Care (2010) 0.75
The case for expanding human immunodeficiency virus testing. Mayo Clin Proc (2006) 0.75
Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network. AIDS Res Treat (2013) 0.75
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One (2013) 0.75
Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients. AIDS Clin Care (2005) 0.75
Report on the XIV International AIDS Conference. AIDS Clin Care (2002) 0.75
Report from the 13th retrovirus conference. Extending the role of atazanavir. AIDS Clin Care (2006) 0.75
Top stories of 2004. Bad nukes comes in threes. AIDS Clin Care (2005) 0.75
Meeting notes from ICAAC. Prevalence and predictors of R5 and X4 tropism. AIDS Clin Care (2005) 0.75
Report from the 13th retrovirus conference. Expanding HIV testing. AIDS Clin Care (2006) 0.75
Meeting report from the XV International AIDS Conference. Clinical trials of approved antiretrovirals. AIDS Clin Care (2004) 0.75
Report from the 12th Retrovirus Conference. Studies of approved antiretrovirals. AIDS Clin Care (2005) 0.75
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC. AIDS Clin Care (2005) 0.75
Meeting notes from the 3rd IAS Conference. New drugs. AIDS Clin Care (2005) 0.75
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s). AIDS Res Hum Retroviruses (2010) 0.75
Meeting notes from ICAAC. Promising early results for a novel CCR5 antagonist. AIDS Clin Care (2005) 0.75